Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 billion through 2027. | The company added an extra $1.7 billion to its "cost ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...